ABSTRACT
Bioresorbable scaffolds offer the possibility of transient scaffolding of the vessel to prevent acute vessel closure and recoil while also transiently eluting an antiproliferative drug to counteract the constrictive remodeling and excessive neointimal hyperplasia. The concept of a transient coronary device that disappears after doing its job fits the physiological demand to restore the vessel structure and seems attractive both to physicians and patients. Following the successful and intriguing findings observed in the first-in-human trials, the four products, Absorb, Desolve, ART, and Magmaris scaffolds succeeded to acquire a CE mark.
